

10th Annual Hepatitis and Chronic Liver Disease Seminar

|  |  |  |  |
| --- | --- | --- | --- |
| **Conference****Location** | **Fort Lauderdale, FL – May 31, 2025**

|  |  |
| --- | --- |
| **The Westin Fort Lauderdale Beach Resort**321 N Fort Lauderdale Beach BlvdC Fort Lauderdale, Florida 33304  |  **Phone: (954) 467-1111**[https://www.marriott.com/en-us/hotels/flllw-the-westin-fort-lauderdale-beach-resort/overview/](https://url.avanan.click/v2/___https%3A//www.marriott.com/en-us/hotels/flllw-the-westin-fort-lauderdale-beach-resort/overview/___.YXAzOndjLWl0Z3JvdXA6YTpvOjdjNjZlZmE5MjU4MTQzYmQ3YTIzNTMwMTkzYjI5ZGUxOjY6ZTI0Nzo0YTBlM2JkNDQ4ODgyZmI5MzFiYWMxNWM3ZDlmZjc4MWY4NTU5N2JhMzVlMDJmNTI3Y2U1MDExZTAzYjdkZTNjOnA6VDpO) |

 |
| **Parking at the Conference** | Special discounted valet parking rate of $18 for meeting attendees. |
| **Driving Directions** | Follow US 1 South to East Las Olas Boulevard |
| **Seminar Agenda and Syllabus Information**  | Registration begins at **7:30 a.m.** in the Oceanside Ballroom. **The Hepatitis and Chronic Liver Disease seminar is a paperless program**. The **course syllabus and related materials will be made available on a digital app** that can be accessed by a smart phone, tablet or personal computer. Instructions to download the *App* will be provided. Wi-Fi will be available without charge. |
| **Pre-Program Assignments** | **Pre-Lecture 1 - 2025 Viral Hepatitis Update –** A summary for discovery and natural history of viral hepatitis (25 mins)**Pre-Lecture 2 - End Stage Liver Disease**: A systematic overview of Treatment, Managing Complications chronic liver disease, cirrhosis, and the transplant process (45 mins) |
| **7:30 am** | ***Registration and View Exhibits*** |
| **8:00 am** | **Opening Comments and Pre-Test** |
| **8:25 am** | **Hepatitis C-Elimination and Care for Special Populations**  * Recap the highlights of Pre-Lecture 1
* Viral Hepatitis Elimination - Caring for At-risk populations – homeless, PWID, the incarcerated, HIV-infected individuals
* Approved Direct Acting Antivirals
* The vital role of specialty pharmacy
* Clinical Cases and Discussion: HCV and At-Risk Individuals
 |
| **9:05 am** | **Hepatitis B: Epidemiology, Natural History, Testing and Therapies** * Efficacies and opportunities in HBV testing and vaccination.
* Disease progression and impact on liver health
* The efficacy of HBV Vaccination
* Anti-viral therapies of HBV
* HBV Re-activation
* Latest studies from EASL and AASLD
 |
| **9:40 am** | **Delta Hepatitis and Hepatitis E Update** * Global and US perspective on the rapid growth of Delta Hepatitis
* Bulevirtide for Delta Hepatitis
* Testing and surveillance approaches
* Real world outcome studies on HDV and HEV
 |
| **10:15 am** | ***Disease Awareness Session –presented by Alexion/AstraZeneca Rare Diseases – Overview of LAL-D***Break and View Exhibits |
| **11:00 am** | **End Stage Liver Disease: Recap and Clinical Cases** * A review of Pre-course lecture on end-stage liver disease
* Complications of cirrhosis
* Liver transplant in the era of DAA’s
* Clinical cases to illustrate HE. HRS and/or Thrombocytopenia
 |
| **11:30 am** | **Hepatocellular Carcinoma (HCC) - Disease Progression in the US*** Screening diagnostic serum assays and imaging tests
* Treatment and management options: Ablation, TACE and Surgery
* New studies showing cost effectiveness of surveillance post SVR
* PRIUS Study (MRI vs US) Abbreviated MRI
* 2024 AASLD screening guidance for liver cancer. New guidelines are less critical of liver biopsy for cancer detection
 |
| **12:00 pm** | **Hepatocellular Carcinoma: New Systemic Treatment Options** * **A case-based approach to HCC treatment**
* Promising 1st and 2nd line therapies for liver cancer
* New data on the benefit of downstaging
* New chemotherapy regimens in development and Immunotherapy as the new HCC MoA
* Checkpoint inhibitors and VEGE inhibitors
 |
| **12:30 pm** | ***Lunch and Industry Presentation by Ipsen Pharmaceuticals - Unlocking Treatment Possibilities for PBC*** Dessert & View Exhibits |
| **1:15 pm** | **Cholestatic Liver Disease: Primary Biliary Cholangitis, Primary Sclerosing Cholangitis and Pruritus** * Predicting outcomes and Improving Survival in PSC patients
* Coping with the clinical features of PBC
* Ursodeoxycholic Acid (UDCA) and Obetacholic Acid
* Highlights of the ELATIVE, RESONSE and ASSURE studies on PBC

Understanding cholestatic pruritus and helping patients cope with the itching |
| **2:10 pm** | **Alcohol Associated Liver Disease** * The growing prevalence of alcohol over-consumption and its impact on liver health
* Alcohol consumption and malnutrition
* Promising therapeutic agents for AAH and other alcohol associated liver disease
 |
| ***2:45 pm*** | * ***Break and Exhibits***
 |
| **3:00 pm** | **Steatotic Liver Disease: The new healthcare epidemic** * New naming conventions for fatty liver disease: MASLD and MASH– what and why?
* Epidemiology, Demographics and Diagnosis
* Scoring, Staging and Management of Metabolic Liver Disease
* The ‘unhealthy” rise in MASLD in the US population and What can be done
 |
| **3:40 pm** | **MASH Treatments in Practice and in Development** * Current therapies for NASH including Updates from AASLD and EASL
* Lifestyle changes as a therapy
* Drugs in clinical development for NASH – Semaglutide and Resmeterom

MASH Diagnosis and Treatment case |
| **4:25 pm** | **Closing Comments, Post-test and Wrap-Up**  |
| **Post Program Lectures:** | **Lecture 3 - Fluid Management, Ascites and Hepatorenal Syndrome (**30 mins) **Lecture 4 – AASLD Update – Highlights of the 2024 AASLD Liver Meeting (**80 mins) |
| **Attendance Policies** | **Attendee Cancellation, Substitution, Refund**The course tuition is refundable, minus a $20 processing fee, if your cancellation is received in writing no later than seven days prior to the conference. Attendee substitutions are allowed, but notification must be made in writing seven days prior to the conference. After that date, no refunds, credits, or substitutions will be granted. No refunds or credits will be given to those who “no show.” **Recording and Photography** The Colorado Medical Society reserves exclusive rights to record (audio and video) and/or photograph conference proceedings for use in marketing materials, future presentations and other purposes.**Guest Attendance** All conference activities (including educational sessions, meal functions, exhibit hall participation and others) are exclusively reserved for seminar participants. Non-registered guests (including children, family members, colleagues, and others.) are not permitted in the seminar areas. **Conference Modification or Cancellation****The Colorado Medical Society and SC Liver Research Consortium reserve the right to modify the course’s schedule, faculty or content if necessary. They also reserve the right to cancel this seminar, and in the unlikely event, a full refund of the registration fee will be provided.** We are unable to refund any travel costs (flight, hotel, etc.) in the case of a seminar cancellation.  |
| **CME Information** | **Physicians (MD/DO**) - The Colorado Medical Society Office of Continuing Medical Education & Professional Development designates this live activity for a maximum of **10.0 *AMA PRA Category 1 Credit(s)*™.** Physicians should claim only the credit commensurate with the extent of their participation in the activity.**Nurse Practitioners and Physician Assistants** - AANP and AAPA accept Category I credit from AMA PRA Category 1 Credit(s)™ organizations accredited by ACCME. |
| **Your Seminar Faculty** | **BINU JOHN, MD, MPH**Dr. Binu John is an Associate Professor of Medicine at the University of Miami, and Associate Chief of Medicine, Chief of Gastroenterology and Hepatology, and Director of the CSP-NODES at the Miami VA Health System. He is also a practicing gastroenterologist and hepatologist with a broad background in clinical, outcomes and translational research, with specific training in epidemiology and clinical research. Dr John’s research is focused on hepatocellular carcinoma (HCC), viral hepatitis, and cirrhosis of the liver, and has expertise, leadership experience, clinical training, temperament and strong motivation to carry out successfully this proposed work. It is my research goal to improve the early identification of patients with chronic liver disease, with the goal of early intervention to improve liver-related outcomes. **PATRICIA D. JONES, MD**Dr. Patricia Jones is a Hepatologist and Associate Professor of Clinical Medicine at the University of Miami’s Miller School of Medicine. Receiving her medical degree from Albany College of Medicine and completed fellowships in both for Gastroenterology and Transplant Hepatology at the University of North Carolina.Dr. Jones joined the University of Miami faculty in 2015. She takes a multi-pronged approach to researching disparities in hepatocellular carcinoma (HCC) and chronic liver disease. She used community-based participatory research to test the feasibility and acceptability of home-based hepatitis B screening. Dr. Jones established a prospective database and biorepository of diverse patients with chronic liver disease, cirrhosis, and HCC, which has supported various studies aimed at understanding the needs and perspectives of patients. **CARLA MOLLINER, PA**Carla Molliner is a nationally certified physician assistant specializing in hepatology at the University of Miami, Hepatology division. She graduated and completed PA school from Miami-Dade College in 2004 then earned her Master of Medical Science degree at Nova Southeastern University. She holds the national board recertification examination by the National Commission for Certification of Physician Assistants.Carla was awarded an NP/PA clinical Hepatology fellowship from the American Association for the Study of Liver Disease (AASLD) between 2005 and 2006. Followed by joining the University of Miami in the outpatient Hepatology clinic. She then joined the inpatient hepatology consult team, and has been an integral member for the past six years.  |